Teva Pharma Ind Shs Sponsored American Deposit Receipt Repr 1 Sh $54.60

up +0.20


29/7/2014 01:13 PM  |  NYSE : TEVA  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get TEVA Trend Analysis - it has outperformed the S&P 500 by 17%

Partner Headlines

  1. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  2. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  3. George Soros Reveals His Largest Stake

    GuruFocus
  4. Sofinnova Ventures Closes $500M Fund

    FoxBusiness
  5. Israel's Market Appears Unfazed By Rising Conflict

    IBD
  6. George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps Selling GOOGL, ...

    GuruFocus
  7. UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler

    Benzinga
  8. 4 Top Performing Health Care Stocks With More Potential Upside

    Benzinga
  9. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  10. Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest ...

    Benzinga
  11. Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd

    GuruFocus
  12. Diamond Hill Select Fund Commentary - First Quarter 2014

    GuruFocus
  13. Teva Pharmaceutical

    IBD
  14. Generic-Drug Makers Climb Ranks; Several In Buy Range

    IBD
  15. Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

    Benzinga
  16. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga
  17. Top Guru Held Asian Companies of the First Quarter

    GuruFocus
  18. Teva to buy Labrys Biologics

    IBD
  19. Chicago sues painkiller firms

    IBD
  20. Benzinga's M&A Chatter for Tuesday June 3, 2014

    Benzinga
  21. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  22. Richard Snow's Top Five Highlight Finance and Healthcare Sectors

    GuruFocus
  23. Benzinga's M&A Chatter for Wednesday May 7, 2014

    Benzinga
  24. ETF Outlook For Tuesday May 6, 2014 (EUFN, ITA, EIS, UAE)

    Benzinga
  25. Wrong Marketing Lesson by Big Pharma

    GuruFocus
  26. Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries Ltd.

    Benzinga
  27. Teva EPS tops; rivals seen?

    IBD
  28. Market Wrap For May 1: Markets Mixed To Start The New Month

    Benzinga
  29. Earnings Scheduled For May 1, 2014

    Benzinga
  30. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  31. Actavis Reporting Q1 Earnings Amid Merger Frenzy

    IBD
  32. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  33. Morning Market Losers

    Benzinga
  34. Benzinga's Top #PreMarket Losers

    Benzinga
  35. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase III SYNERGY ...

    Benzinga
  36. Nasdaq Could Be in for a Bounce

    FoxBusiness
  37. Actavis got a Pfizer

    IBD
  38. Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received Tenative ...

    Benzinga
  39. Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

    Benzinga
  40. Teva Unveils Generic Lunesta Tablets in US

    Benzinga
  41. Teva Announces First Approval and Launch of Generic Lovaza® Capsules in ...

    Benzinga
  42. Market Wrap For April 7: Bears In Complete Control As Markets Get Hammered ...

    Benzinga
  43. Citigroup Slaps $70 Price Target on Teva, Highest on Street

    Benzinga
  44. Market Wrap For March 31: Stocks Rally As Yellen Confirms Support For Economy

    Benzinga
  45. Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma

    Benzinga
  46. Market Wrap For March 28: Markets Still Positive Despite Giving Up Early ...

    Benzinga
  47. Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

    Benzinga
  48. UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries

    Benzinga
  49. Forest Laboratories' Recovery

    GuruFocus
  50. Should You Buy Actavis?

    GuruFocus
Trading Center